Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure

Transplantation

Volumn 72, Issue 5, 2001, Pages 777-786

  Johnson, Robert W G ^a   Kreis, Henri ^b   Oberbauer, Rainer ^c   Brattstrom, Christina ^d   Claesson, Kerstin ^e   Eris, Josette ^f  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^f ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; RAPAMYCIN; STEROID;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HERPES ZOSTER; HUMAN; HYPERTENSION; HYPERURICEMIA; HYPOKALEMIA; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; SURVIVAL RATE; THROMBOCYTOPENIA;

EID: 0035884710     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200109150-00007     Document Type: Article

References (37)

1. Rapamune (Sirolimus, rapamycin): An overview and mechanism of action
2. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK 506 complexes
3. Neointimal formation after balloon-induced vascular injury in Yucatan minipigs is reduced by oral rapamycin
4. Sirolimus (rapamycin) halts and reverses progression of allograft vascular disease in non-human primates
5. Synergistic mechanisms by which sirolimus and cyclosporin inhibit rat heart and kidney allograft rejection
6. The effect of rapamycin on kidney function in the Sprague-Dawley rat
7. Effects of rapamycin on renal hemodynamics, water and sodium excretion, and plasma levels of angiotensin II, aldosterone, atrial natriuretic peptide, and vasopressin in pigs
8. Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model
9. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: A phase II trial
10. Efficacy of sirolimus compared with azathioprine for the reduction of acute renal allograft rejection: A randomized multicentre study
11. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts
12. The side effect profile of sirolimus: A phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients
13. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine
14. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients
15. An immunoassay for the measurement of sirolimus
16. Therapeutic monitoring of sirolimus in human whole-blood samples by high-performance liquid chromatography
17. Validation of an assay for routine monitoring of sirolimus using HPLC with mass spectrometric detection
18. Proficiency testing issues related to sirolimus
19. International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology
20. Predicting glomerular filtration rate after kidney transplantation
21. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge
22. A meta-analysis of immunosuppressive withdrawal trials in renal transplantation
23. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for the prevention of acute rejection
24. Multicentre randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection
25. Randomized trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients
26. Determinants of chronic renal allograft rejection in cyclosporine treated recipients
27. Arterial hypertension and renal allograft survival
28. Association of chronic kidney graft failure with recipient blood pressure
29. Cyclosporin A impairs the nocturnal blood pressure fall in renal transplant recipients
30. New insights into the pharmacodynamic and pharmacokinetic properties of statins
31. Cardiovascular disease after renal transplantation
32. Clinical risk factors associated with nonmelanoma skin cancer in renal transplant recipients
33. Activation of p70 ribosomal protein S6 kinase is an essential step in the DNA damage-dependent signaling pathway responsible for the ultraviolet B-mediated increase in interstitial collagenase (MMP-1) and stromelysin-1 (MMP-3) protein levels in human dermal fibroblasts
34. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil: A prospective randomized study
35. Sirolimus-tacrolimus combination immunosuppression
36. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen